Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Cardiovascular safety of high doses of the nebulized bronchodilators in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004
Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
Efficacy and cardiovascular safety of long-term bronchodilator therapy with theophylline in patients with chronic obstructive bronchitis (COB) Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014
Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma Source: Annual Congress 2009 - Epidemiology of atopy and asthma Year: 2009
Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015
Combination therapy of inhaled corticosteroids and long-acting beta2 -agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking Source: Eur Respir J 2006; 28: Suppl. 50, 454s Year: 2006
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2 -agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019